Skip to content
Independent analysis of NHS open data
PharmaInsight

Vutrisiran 25mg/0.5ml solution for injection pre-filled syringes

Secondary Care Medicines Data (SCMD) · indicative cost
Data updated April 2026

NHS hospitals in England used £83,112,666 of indicative cost of Vutrisiran 25mg/0.5ml solution for injection pre-filled syringes in the 12 months to April 2026, about 0.3% of all hospital medicines spend. That is up 4.2% on the previous 12 months.

£83,112,666 +4.2%

Indicative cost · 12 months

434units

Quantity (VMP units) · 12 months

0.3%

Share of hospital medicines spend

Figure 1. Vutrisiran 25mg/0.5ml solution for injection pre-filled syringes: NHS hospital indicative cost by month (£ millions)

£0m £4.5m £8.9m Apr 2023 Oct 2023 Apr 2024 Oct 2024 Apr 2025 Oct 2025 Apr 2026 £6.0m Apr 2023: £1.7m May 2023: £4.0m Jun 2023: £4.7m Jul 2023: £2.9m Aug 2023: £4.9m Sep 2023: £5.2m Oct 2023: £4.0m Nov 2023: £8.0m Dec 2023: £6.5m Jan 2024: £3.8m Feb 2024: £8.3m Mar 2024: £5.5m Apr 2024: £4.3m May 2024: £7.8m Jun 2024: £6.1m Jul 2024: £6.7m Aug 2024: £7.8m Sep 2024: £7.1m Oct 2024: £5.2m Nov 2024: £6.3m Dec 2024: £8.6m Jan 2025: £6.3m Feb 2025: £5.6m Mar 2025: £7.1m Apr 2025: £5.2m May 2025: £8.0m Jun 2025: £6.3m Jul 2025: £6.7m Aug 2025: £7.6m Sep 2025: £7.9m Oct 2025: £4.9m Nov 2025: £3.2m Dec 2025: £8.9m Jan 2026: £7.2m Feb 2026: £7.8m Mar 2026: £8.7m Apr 2026: £6.0m

Source: NHSBSA Secondary Care Medicines Data, to April 2026

Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.

NHS trusts using Vutrisiran 25mg/0.5ml solution for injection pre-filled syringes most

By indicative cost over the 12 months to April 2026.

NHS trusts using Vutrisiran 25mg/0.5ml solution for injection pre-filled syringes most, by indicative cost
NHS trustIndicative cost (12 months)
Royal Free London Nhs Foundation Trust £83,112,666

The primary-care picture

No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.